Logo image
Hypertonic saline in non–cystic fibrosis bronchiectasis (Hyper-BRONCHI): an updated systematic review and meta-analysis
Journal article   Open access   Peer reviewed

Hypertonic saline in non–cystic fibrosis bronchiectasis (Hyper-BRONCHI): an updated systematic review and meta-analysis

Nhan Nguyen, Yacin Zawam, Nghi Bao Tran, Nathalia Alves de Barros e Lyra, Vinh Quang Tri Ho, David Downes, Vy Ngoc Dan Nguyen, Ha Duc Thien Le and Jafar Aljazeeri
BMC pulmonary medicine, v 26(1), 122
12 Feb 2026
PMID: 41673600
url
https://doi.org/10.1186/s12890-026-04176-4View
Published, Version of Record (VoR) Open CC BY V4.0

Abstract

Systematic Review
Question: Does inhaled hypertonic saline (HS) provide better lung function outcomes for patients with non-cystic fibrosis bronchiectasis (non-CF bronchiectasis) ? Finding: Overall, hypertonic saline (HS) yielded outcomes comparable to those of the non-HS group (including isotonic saline or standard of care) with respect to FEV₁, FVC, and the annual number of pulmonary exacerbations. These findings were consistent during long-term follow-up of up to 52 weeks. Meaning: Up to date, the data on HS inhaled therapy for non-CF bronchiectasis is limited in high-quality studies, highlighting the need for further non-CF bronchiectasis-specific RCTs, focusing on HS of NaCl 6–7%.

Metrics

1 Record Views

Details

UN Sustainable Development Goals (SDGs)

This publication has contributed to the advancement of the following goals:

#3 Good Health and Well-Being

Source: SDGs in the Output

InCites Highlights

Data related to this publication, from InCites Benchmarking & Analytics tool:

Collaboration types
Domestic collaboration
International collaboration
Web of Science research areas
Respiratory System
Logo image